COTA Promotes Paige Whitney to Senior Vice President to Expand the Use of Real-World Data in Life Sciences
Paige Whitney will join the executive leadership team as Senior Vice President of Life Sciences. Paige is responsible for growing the company’s industry partnerships and strengthening COTA’s position as a leading provider of oncology RWD.
Patient-Centered Drug Development Leads the Way in 2022
This will be the year that patient centricity drives drug development and care delivery decisions.
COTA Extends Research Collaboration Agreement With The U.S. Food and Drug Administration
COTA has extended its Research Collaboration Agreement (RCA) with the U.S. Food and Drug Administration (FDA) for an additional three years. This renewed RCA will expand on the objective to explore the applications of real-world data in oncology.
COTA Supports FDA Assessment of Real-World Data through Membership in COVID-19 Evidence Accelerator
Leveraging its past knowledge of real-world evidence applications and learnings, COTA has joined the COVID-19 Evidence Accelerator program, a joint initiative of Friends of Cancer Research (Friends) and the Reagan-Udall Foundation for the Food and Drug Administration. Through this initiative, COTA is delivering findings from its observational, real-world studies using data from over 3,000 patients hospitalized with COVID-19 within the Hackensack Meridian Health network.
Celebrating the Nurses at COTA During National Nurses Week
In recognition of National Nurses Week, we’ve asked COTA’s nurses a few questions about their motivation for becoming a nurse, how their current roles in healthcare technology differs from their experience working in the hospital, and their message to nurses currently on the frontlines of the pandemic.
COTA Signs Research Collaboration Agreement With The U.S. Food and Drug Administration
Collaboration Aims to Study Variation in Cancer Treatment Patterns by Extracting and Analyzing Real-World Data
